Tag Archives: Alnylam

Novo Nordisk, Tandem, Alnylam, and Regeneron Q1 ’23 Earnings

Four cardiometabolic-related news items have been observed: Novo Nordisk (view press release; slides), Tandem Diabetes Care (view press release), Alnylam Pharmaceuticals (view press release; slides), and Regeneron (view press release; slides) hosted their respective Q1 ’23 earnings calls and provided CVRM-related updates. Below, FENIX provides highlights and insights from the earnings calls.

This content is for Read Less members only.
Register
Already a member? Log in here

Medtronic InPen App Recall; Libre 3 + Ypsomed AID Available in Germany; Altimmune Positive Pemvidutide NAFLD Data; Embecta CY Q3 ’22 Earnings Update; Alnylam Submits ALN-KHK CTA for T2DM; Biocorp Receives EU Medical Device Certification

A series of cardiometabolic-related news items have been observed from Medtronic, Abbott, Altimmune, Embecta, Alnylam, and Biocorp. Below, FENIX provides highlights and insight on the respective news items, including thoughts on the Medtronic recall and how the positive Altimmune NAFLD data may not be enough.

This content is for Read Less members only.
Register
Already a member? Log in here

Alnylam Hosts 2022 R&D Day; Movano Health Initiates First Beta Program for Smart Ring

Two cardiometabolic-related news items have been observed: Alnylam hosted its 2022 R&D webinar and provided clinical and commercial updates (view press release; slides); and Movano Health announced the launch of its Movano Ring beta program with Novant Health (view press release). Below, FENIX provides highlights and insights on the two news items, including thoughts on Alnylam’s clinical and preclinical pipeline.

This content is for Read Less members only.
Register
Already a member? Log in here

Teladoc, Alnylam, and Amarin Q3 ’22 Earnings Updates

A series of cardiometabolic-related news items have been observed: Teladoc (press release; slides), Alnylam (press release; slides), and Amarin (press release; slides) hosted their Q3 ’22 earnings calls. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Alnylam and Regeneron to Advance NASH ALN-HSD Asset

Alnylam and Regeneron announced initial Part B data from the ALN-HSD Ph1 NASH study (view CT.gov record) and disclosed plans to initiate Ph2 development in late 2022. Recall, during its November 2021 R&D webinar, Alnylam highlighted 14-week HSD17B13 knockdown results from Part A of the ALN-HSD Ph1 study (previous FENIX insight). Below, FENIX provides context and insight on the latest ALN-HSD data readout.

This content is for Read Less members only.
Register
Already a member? Log in here

Novo’s QW Insulin Icodec Meets Primary Endpoints in ONWARDS 3 and 4; AZ and Alnylam Q2 ’22 earnings updates; Better Therapeutics Meets Secondary Endpoint in BT-001 Pivotal Trial in T2DM

A series of cardiometabolic-related news items have been observed: Novo announced topline results from the QW insulin icodec Ph3 ONWARDS 3 and ONWARDS 4 trials in T2DM; AZ (press release; slides) and Alnylam (press release; slides) hosted their respective earnings calls; and Better Therapeutics (BT) announced positive secondary endpoint results for its BT-001 pivotal clinical trial in T2DM and held an associated investor call (view webcast). Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here

Senseonics Announces FDA Review for 180-day CGM Nearing Completion; Alnylam and Novartis Announce Collaboration for Liver Failure

Two cardiometabolic-related news items have recently been observed: Senseonics announced updates to its business, including an anticipated PMA supplement approval for its Eversense 180-day CGM “in the coming weeks”; and Alnylam and Novartis announced an exclusive three-year research collaboration to develop an siRNA-based targeted therapy for end-stage liver diseases. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here